Linsitinib (OSI-906)是一种口服活性、有效且选择性的IGF-1/胰岛素受体（IR）双重抑制剂。
|
英文别名 (English Synonym) |
Linsitinib |
|
中文名称 (Chinese Name) |
林西替尼 |
|
靶点 (Target) |
Insulin Receptor |
|
通路 (Pathway) |
Protein Tyrosine Kinase |
|
CAS号 (CAS NO.) |
867160-71-2 |
|
分子式 (Formula) |
C26H23N5O |
|
分子量 (Molecular Weight) |
421.51 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2009 Sep,1(6):1153-71. doi: 10.4155/fmc.09.89. PMID: 21425998.[2]McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011 May 15,17(10):3332-40. doi: 10.1158/1078-0432.CCR-10-2274. Epub 2011 Jan 21. PMID: 21257723, PMCID: PMC3122480.
